Novartis signs deal to boost cell therapy portfolio
ZURICH (Reuters) - Swiss drugmaker Novartis AG said on Friday it had signed a licensing and research deal that could boost its ability to develop innovative cell-based therapies for conditions where little treatment is currently available.
The maker of blockbuster blood pressure drug Diovan said it would use a stem-cell based platform developed by U.S.-based biopharmaceutical company Regenerex to help broaden its cell therapy portfolio.
Timothy Wright, head of development at Novartis Pharmaceuticals, said the agreement would support Novartis' leadership position in cell therapy.
- Malaysian plane presumed crashed; questions over false IDs |
- China draws 'red line' on North Korea, says won't allow war on peninsula
- Warning shots fired to turn monitors back from Crimea |
- Libya threatens to bomb North Korean tanker if it ships oil from rebel port